Latest Mergers And Acquisitions News

Oldfields Holdings Limited reports a robust second quarter for FY2025, highlighting successful strategic realignment and improved financial performance despite ongoing transition costs.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Great Northern Minerals Limited reports significant progress in the sale of its Golden Ant Mining project, with a $1.3 million Earn-In Stage payment expected soon, alongside notable board changes and strategic project reviews.

Duxton Farms Limited reported a robust Q2 FY2025, driven by favourable weather conditions and strategic investments, including a share buyback and increased stakes in agricultural ventures. The company recorded a $2.24 million operating cash flow surplus amid mixed crop yields and ongoing diversification.

MPower Group has finalized the conversion of a $10 million project funding facility for its Narromine Renewable Energy Project into equity, with AMPYR Distributed Energy acquiring full ownership. The move strengthens MPower's balance sheet and supports its strategic push into hybrid renewable assets.

South Harz Potash Limited has made significant strides in acquiring the Sollstedt mine and secured approximately A$2.2 million in new equity, positioning itself to advance the Ohmgebirge project amid a strengthening potash market.

Rare Foods Australia reports an 18% biomass increase and $440k in cost savings, while launching its Subsea Estate brand and securing a $2.1M R&D refund to support growth.

RooLife Group (ASX: RLG) reported a striking 144% increase in sales revenue for Q2 FY2025, driven by the launch of new online stores across China, Hong Kong, Australia, and India. The company is investing heavily in product development and marketing to capitalize on booming health and wellness markets.

Red Sky Energy's December 2024 report reveals steady production from Yarrow 3, imminent fracture stimulation at Yarrow 1, and a transformative 35% stake in Angola's Block 6/24, positioning the company for diversified growth and enhanced cash flow.

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Jade Gas Holdings has made significant strides in its coal bed methane project in Mongolia, completing key wells and securing A$3.63 million to accelerate its gas production strategy targeting 2025 gas flows.

Elsight reported a robust 32% increase in annual revenue for 2024, driven by a strategic pivot towards the defense sector, which now accounts for over half of its total revenue. The company’s expanding customer base and debt elimination position it well for growth in 2025.